Biohaven Stock Forecast
NYSE: BHVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BHVN analyst consensus
Consensus (17 analysts)
buy
Avg. price target
$21.27+76.08%
- Strong buy 3
- Buy 9
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 17 Wall Street analysts covering Biohaven (2026-10-10), 12 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $21.27, with a high estimate of $42.00 and a low estimate of $10.00. The average target implies upside of 76.1% from the current price of $12.08.
The spread between the highest and lowest targets is 320.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BHVN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 18% |
| Buy | 9 | 53% |
| Hold | 4 | 24% |
| Sell | 0 | 0% |
| Strong sell | 1 | 6% |
Ratings as of 2026-10-10.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $10.00 | -17.22% |
| Average target | $21.27 | +76.08% |
| High target | $42.00 | +247.68% |